mAbxience and Biosidus Sign CDMO Agreement for the Manufacture of Agalsidase Beta for the Treatment of Fabry DiseaseMiguel Martínez-Cava2024-02-05T11:58:27+01:00February 5, 2024|Press releases|
mAbxience Announces Licensing Agreement with Intas Pharmaceuticals Ltd. for Etanercept Biosimilar Targeting Autoimmune Diseases in more than 150 Countries, including Europe and the United States of AmericaMiguel Martínez-Cava2023-12-20T10:49:24+01:00December 20, 2023|Press releases|
mAbxience and Abdi İbrahim Announce Landmark Technology Transfer Agreement, Advancing Biotechnology in TürkiyeMiguel Martínez-Cava2023-11-20T08:43:23+01:00November 20, 2023|Press releases|
The Future of Biosimilars: Trends and PredictionsMiguel Martínez-Cava2024-02-26T08:56:52+01:00February 26, 2024|News|
Improving Drug Development: The Strategic Value of CDMO PartnershipsMiguel Martínez-Cava2024-02-12T10:05:10+01:00February 12, 2024|News|
The Evolution of Biopharmaceutical ManufacturingMiguel Martínez-Cava2024-01-22T08:38:03+01:00January 22, 2024|News|